12:00 AM
 | 
Mar 04, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Affymax, Takeda sales and marketing update

Affymax and partner Takeda voluntarily recalled Affymax's once-monthly anemia drug Omontys peginesatide after receiving new postmarketing reports of serious hypersensitivity reactions that can be life-threatening or fatal. The partners said no new or existing patients should receive Omontys. The recall includes both IV and subcutaneous formulations of Omontys. According to the partners, the overall rate of hypersensitivity reactions is about 0.2% in the more than 25,000 patients that have received...

Read the full 338 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >